GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmiva AB (OSTO:PHARM) » Definitions » Debt-to-Revenue

Pharmiva AB (OSTO:PHARM) Debt-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Pharmiva AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharmiva AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was kr0.00 Mil. Pharmiva AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was kr0.00 Mil. Pharmiva AB's annualized Revenue for the quarter that ended in Jun. 2023 was kr3.59 Mil. Pharmiva AB's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.00.


Pharmiva AB Debt-to-Revenue Historical Data

The historical data trend for Pharmiva AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmiva AB Debt-to-Revenue Chart

Pharmiva AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
N/A N/A - -

Pharmiva AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharmiva AB's Debt-to-Revenue

For the Biotechnology subindustry, Pharmiva AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmiva AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmiva AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharmiva AB's Debt-to-Revenue falls into.



Pharmiva AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharmiva AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Pharmiva AB's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2023) Revenue data.


Pharmiva AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharmiva AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmiva AB (OSTO:PHARM) Business Description

Traded in Other Exchanges
N/A
Address
Sankt Lars Väg 45B, Lund, SWE, 222 70
Pharmiva AB is a medical technology company. It develops innovative antibiotic-free medical products in order to improve vaginal health.

Pharmiva AB (OSTO:PHARM) Headlines

No Headlines